Loading, please wait...
________________________________________________________________________________
Meeting ID: 219 425 022 467
Passcode: iZ7KH9AT
For organizers: Meeting options
________________________________________________________________________________
Date: Mar 6, 2025 02:00 PM - 03:00 PM
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Registration closes on Mar 13, 2025 11:55 PM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
WellStar Health System is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
Participants who attend the entire activity, complete and pass the post-test (>70%) and complete the activity evaluation will receive CE credit.
Credit will be uploaded electronically and be available in CPE Monitor after completion of required elements.
________________________________________________________________________________
Meeting ID: 219 425 022 467
Passcode: iZ7KH9AT
For organizers: Meeting options
________________________________________________________________________________
Objectives
- 1. State the mechanism of action and pathophysiology for both Andexanet alfa and 4 factor prothrombin complex concentrates (4F-PCCs) for direct oral anticoagulant (DOAC) reversal
- 2. Evaluate guideline recommendations and other published literature regarding the use of Andexanet alfa and 4F-PCCs for DOAC reversal
- 3. Analyze dosing strategies and drug properties of DOACs, Andexanet alfa, and 4F-PCCs
- 4. Apply evidence-based medicine and drug knowledge to the clinical application of DOAC reversal management
Speaker(s)/Author(s)
|
Andrew Norton, PharmD
|
Activity Number
0483-0000-25-004-L01-P
Date:
03/06/25
Time:
02:00 PM - 03:00 PM
CE Hours
1.00
Location
Wellstar MCG Health and via Microsoft Teams